Evaluating Novel Biomarkers in Acute Kidney Injury
Recruitment status was Not yet recruiting
The investigators have a new technique of looking at urine to see whether it contains protein fragments that are released by damaged kidneys. These fragments seem to be more accurate than the current blood tests that the investigators use to diagnose renal failure. This technique needs to be validated with a group of patients that have a relatively high incidence of renal failure, cardiopulmonary bypass.
The investigators hypothesise that using novel markers of renal dysfunction will identify patients who go on to develop renal failure earlier, and in a higher number than the standard blood tests.
The investigators aim to collect urine from patients before going onto bypass, and then at Day 1 and Day 2 after bypass. This urine will be analysed for protein fragments, as well as other new markers of renal dysfunction. The investigators will also take blood at baseline and for the first two days in Cardiac Intensive Care, and compare the accuracy of the new tests with the 'gold standard' that is creatinine.
Acute Kidney Injury
Other: Proteomic assay
Other: Blood sampling
Other: Biomarker sampling
|Study Design:||Endpoint Classification: Bio-equivalence Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
|Official Title:||Evaluating the Utility of Urinary Proteomics and Novel Biomarkers in Acute Kidney Injury|
- Development of acute kidney injury [ Time Frame: Within two days of cardiopulmonary bypass ] [ Designated as safety issue: No ]Development of AKI will be defined by stage 1 of AKIN criteria (ie serum Creatinine >25% of baseline, or oliguria <0.5ml/kg/hr for 6 hours.
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||April 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Other: Proteomic assay
Please refer to this study by its ClinicalTrials.gov identifier: NCT01573104
|Contact: Robert I Docking, MBChB, FRCAemail@example.com|
|Contact: John Kinsella, MD, FRCAfirstname.lastname@example.org|
|Golden Jubilee National Hospital||Not yet recruiting|
|Glasgow, United Kingdom, G81 4DY|
|Contact: Isma Quasim, MBChB, FRCA 44141 951 5000 email@example.com|
|Sub-Investigator: Robert Docking, MBChB, FRCA|
|Principal Investigator: Isma Quasim, MBChB, FRCA|
|Principal Investigator:||John Kinsella, MD, FRCA||University of Glasgow|